Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radium-223 Re-treatment in CRPC
NCT01934790Phase 2Completed
- Sponsor
- Bayer
- Start
- Dec 2013
- Primary completion
- Jun 2015
- Modality
- Radiopharmaceutical
- Countries
- 7
01
Overview
A Phase 2 trial of radium-223 dichloride in castration-resistant prostate cancer (CRPC), sponsored by Bayer. Started Dec 2013; status: completed.
02
Drugs
radium-223 dichloride
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT01934790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01934790.